Xeljanz (tofacitinib): Initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF–alpha inhibitors - European Medicines Agency (EMA)
abgerufen am 19.05.2025.